Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 18, 1986 - Issue sup48
Submit an article Journal homepage
40
Views
2
CrossRef citations to date
0
Altmetric
Miscellany

Norfloxacin: Targeted Antibiotic Therapy: Proceedings of a Workshop Held in Taormina, Sicily 11 April, 1986

S. Ragnar Norrby
Pages 1-91 | Published online: 02 Jan 2015

References

  • Engle EC, Manes SH, Drlica K. Differential effects of antibiotics inhibiting gyrase. J Bacteriol 149: 92–98, 1982
  • Crumplin GC, Kenwright M, Hirst T. Investigations into the mechanism of action of the antibacterial agent norfloxacin. J Antimicrob Chemother 13 ( Suppl. B): 9–23, 1984
  • Benbrook DM, Miller RV. Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa. Antimicrob Agents Chemother 29: 1–6, 1986
  • Gellert MK, O'Dea MH, Nash HA. DNA gyrase: An enzyme that introduces superhelic turns into DNA. Proc Natl Acad Sci USA 73: 3872–3876, 1976
  • Miller RV, Scurlock TR. DNA gyrase (topoisomerase II) from Pseudomonas aeruginosa. Biochem Biophys Res Commun 110: 694–700, 1983
  • Gellert M. DNA topoisomerases. Ann Rev Biochem 50:879–910, 1981
  • Grüneberg RN, Leigh DA, Brumfitt W. Escherichia coli serotypes in urinary tract infection: Studies in domiciliary, antenatal and hospital practice. In: O'Grady FW, Brumfitt W, eds. Urinary tract infections. London: Oxford University Press, 68–79, 1968
  • Brumfitt W, Hamilton-Miller JMT. A review of the problem of urinary tract infection management and the evaluation of a potential new antibiotic. J Antimicrob Chemother 13 ( Suppl. B): 121–133, 1984
  • Warren JW, Tenney JH, Hoopes JM, Municie HL. Anthony WC. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 146: 719–723, 1982
  • Murray BE, Alvarado T, Kim KH, Vorachit M, Jayanetra P, Levine MM, Prenzel M, Fling M, El-well L, McCracken G, Madrigal G, Odio C, Trabulsi LR. Increasing resistance to trimethoprim-sulfamethoxazole among isolates from Escherichia coli in developing countries. J Infect Dis 152: 1107–1113, 1985
  • Haase D, Urias B, Harding G, Ronald A. Comparative in vitro activity of norfloxacin against urinary tract pathogens. Eur J Clin Microbiol 2: 235–241, 1983
  • Kahn MY, Gruninger RP, Nelson SM, Klicker RE. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents agaainst urinary tract bacterial isolates. Antimicrob Agents Chemother 21: 848–851, 1982
  • Downs J, Andriole VT, Ryan JL. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 21: 670–672, 1982
  • Norrby R, Jonsson M. Antibacterial activity of norfloxacin. Antimicrob Agents Chemother 23: 15–18, 1983
  • Tenney JH, Warren JW. Bactericidal activity of norfloxacin and nine other urinary tract antibiotics against Gram-negative bacilli causing bacteriuria in chronically catheterized patients. J Antimicrob Chemother 11: 287–290, 1983
  • Vuye A. In vitro comparison of norfloxacin with nalidixic acid, Drug Res 33: 1623–1627, 1983
  • Norfloxacin: Activity against urinary tract pathogens and factors influencing the emergence of resistance. J Antimicrob Chemother 13: 315–323, 1984
  • King A, Warren C, Shannon K, Pillips I. In vitro activity of norfloxacin (MK 366). Antimicrob Agents Chemother 21: 604–607, 1982
  • Neu HC, Labthavikul P. In vitro activity of norfloxacin, a quinolone carboxylic acid, compared with that of β-lactams, aminoglycosides and trimethoprim. Antimicrob Agents Chemother 22: 23–27, 1982
  • Cofsky RD, DuBouchet L, Landesman SH. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 26: 110–111, 1984
  • Haase DA, Harding GKM, Thomson MJ, Kennedy JK, Urias BA, Ronald AR. Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial affect on periurethral and fecal microflora. Antimicrob Agents Chemother 26: 481–484, 1984
  • Norrby SR. Pharmacokinetics of norfloxacin: Clinical implications. Eur J Chemother Antibiotics 3: 19–25, 1983
  • Wise R. Norfloxacin—a review of pharmacology and tissue penetration. J Antimicrob Chemother 13 ( Suppl. B): 59–64, 1984
  • Bergeron MG, Thabet M, Roy R, Lessard C, Foucault P. Norfloxacin penetration into human renal and prostatic tissue. Antimicrob Agents Chemother 28: 349–350, 1985
  • Swanson BN, Boppana VK, Vlasses PH, Rotmensch HH, Ferguson RK. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 23: 284–288, 1983
  • Walsh JA, Warren KS. Selective primary health care: An interim strategy for disease control in developing countries. N Engl Med J 301: 967–974, 1979
  • Rhode JE. Why the other half dies: The science and politics of child mortality in the third world. Assignment Children 61/62: 35–67, 1983
  • Rhode JE. Selective primary health care: Strategies for control of disease in the developing world. XV. Acute diarrhea. Rev Infect Dis 6: 840–854, 1984
  • Davidson GP, Barnes GL. Structural and functional abnormalities of the small intestine in infants and young children with rotavirus enteritis. Acta Paediatr Scand 68: 181–186, 1979
  • Bartlett JG. Experimental studies of antibiotic associated colitis. Scand J Infect Dis, Suppl. 22: 11–15, 1980
  • Field M. Regulation of small intestinal ion transport by cyclic nucleotides and calcium. In: Field M, Fordtran JS. Schultz SG, eds. Secretory diarrhea. Bethesda: American Physiological Society 1980, pp. 21–30.
  • Ravdin JI, Guerrant RL. Role of adherance in cytopathogenic mechanisms of Entamoeba histolytica. J Clin Invest 68: 1305–1313, 1981
  • Bachtin M, Nelwan S, Sebodo T. The use of antibiotics in childhood diarrhea. J Trop Ped Environmental Child Health 25: 101–103, 1979
  • Traveler's warning: Entero-Vioform abroad. Med Lett Drug Ther 17: 105–106, 1975
  • Levine MM. Bacillary dysentery—mechanism and treatment. Med Clin North Am 66: 623–638, 1982
  • Walder M. Epidemiology of campylobacter enteritis. Scand J Infect Dis 14: 27–33, 1982
  • Kohl S. Yersinia enterocolitica infections in children. Pediatr Clin North Am 26: 433–443, 1979
  • Keighley MRB, Burdon DW, Arabi Y, Alexander-Williams J, Thompson H, Youngs D, Johnson MM, Bentley S, George RH, Mogg GAG. Randomized controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J 2: 1667–1669, 1978
  • Teasley DG, Gerdin DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee Jr JT. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhoea and colitis. Lancet 2: 1053–1056, 1983
  • Leading article. Antibiotic-associated colitis: The continuing saga. Br Med J 282: 1913–1914, 1981
  • Goosens H, De Mol P, Coigneau H, Levy J, Grados O, Ghysels G, Innocent H, Butzler JP. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), Ru28965 (a new macrolide) and other agents against enteropathogens. Antimicrob Agents Chemother 27: 388–392, 1985
  • Shungu DL, Weinberg E, Gadebusch HH. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob Agents Chemother 23: 86–90, 1983
  • Steffen R, van der Linde F, Gyr K, Schär M. Epidemiology of diarrhoea in travelers. J Am Med Ass 249: 1176–1180, 1983
  • Black FT, Gaarslev K, Ørskov F, Ørskov I, Stenderup A, Stenderup J, Christensen O. Mecillinam, a new prophylactic for traveller's diarrhoea. Scand J Infect Dis 15: 189–193, 1983
  • Kean BH. The diarrhoea of travellers to Mexico. Summary of a five-year study. Ann Intern Med 59: 609–614, 1963
  • Eschevarria P, Blacklow NR, Sanford LB, Cukor GG. Travellers' diarrhoea among American Peace Corps volunteers in rural Thailand. J Infect Dis 143: 767–771, 1981
  • Sack DA, Kaminsky DC, Sack RB, Itotia JN, Arthur RR, Kapikian AZ, Ørskov F, Ørskov I. Prophylactic doxycycline for travellers' diarrhoea. Results of a prospective double-blind study of Peace Corps volunteers in Kenya. N Engl J Med 298: 758–763, 1978
  • Consensus Conference. Travellers' diarrhoea. J Am Med Ass 253: 2700–2704, 1985
  • Merson MH, Morris GK, Sack DA, Wells JG, Felley JC, Sack RB, Creech WB, Kapikian AZ, Gan-garosa EJ. Travellers' diarrhoea in Mexico. A prospective study of physicians and family members attending a congress. N Engl Med J 294: 1299–1395, 1976
  • Taylor DN, Escheverria P, Blaser MJ, Pitarangi C, Blacklow N, Cross J, Weniger BG. Polymicrobial aetiology of travellers' diarrhoea. Lancet 1: 381–383, 1985
  • Freeman LD, Hopper DR, Lathen DF, Nelson DP, Harrison WO, Anderson DS. Brief prophylaxis with doxycycline for the prevention of travellers' diarrhoea. Gastroenterol 84: 276–280, 1983
  • DuPont HL, Evands DG, Rios N, Cabada FJ, Evans Jr DJ, DuPont MW. Prevention of travellers' diarrhoea with trimethoprim-sulfamethoxazole. Rev Infect Dis 4: 533–539, 1982
  • Stenderup J, Ørskov F. Changes in serotype and resistance pattern of the intestinal Escherichia coli flora during travel. Scand J Infect Dis 15: 367–373, 1983
  • Murray BE, Rensimer ER, DuPont HL. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim-sulfamethoxazole. N Engl J Med 306: 130–135, 1982

References

  • Leigh DA, Emmanuel FXS. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin. J Antimicrob Chemother 13, Suppl B: 85–88, 1984
  • Boerema JBJ, Olthof BJ, van Saene HKF. The evaluation of norfloxacin as decontaminating agent in patients with complicated urinary tract infections. Scand J Infect Dis, Suppl. 48: 27–31, 1986
  • Welling GW. β-aspartyl glycine, an indicator of decreased colonization resistance? In: van der Waaij D, Verhoef J, eds. New criteria for antimicrobial therapy. Amsterdam: Excerpta Medica, 65–71, 1979
  • Van der Waaij D. The colonization resistance of the digestive tract in man and animals. In: Fliedner ThM, ed. Clin Exp Gnotobiot, Zbl Bakt, Suppl 7. Stuttgart, New York: Gustav Fischer Verlag, 155–161, 1979
  • Knothe H. The effect of trimethoprim-sulphonamide, trimethoprim and sulphonamide in the occurrence of resistant Enterobacteriaceae in human intestinal flora. Infection 7, Suppl 4: 321–323, 1979
  • Van Saene JJM, van Saene HKF, Geitz JN, Tarko-Smits NJ, Lerk CF. Quinolones and colonization resistance in human volunteers. Pharm Wkbl (Scientific Edition) 8: 67–71, 1986
  • Muytjens HL, van Veldhuizen GL, Welling GW, van der Ros, van de Repe J, Boerema JBJ, van der Waaij D. Selective decontamination of the digestive tract by pipemidic acid. Antimicrob Agents Chemother 24: 902–904, 1983
  • King A, Warren C, Shannon K, Phillips I. The in vitro antibacterial activity of norfloxacin. Antimicrob Agents Chemother 21: 604–6, 1982
  • Marone P, Concia E, Michelone P, Andreoni M, Farina C. In vitro antibacterial activity of norfloxacin against Pseudomonas aeruginosa. Eur J Chemother Antibiot 3: 15–18, 1983
  • Forward KR, Hading GKM, Gray GJ, Urias BA, Ronald AR. Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and resistant Pseudomonas aeruginosa trains. Antimicrob Agents Chemother 24: 602–604, 1983
  • Cofsky RD, duBouchet L, Landesman SH. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 26: 110–111, 1984
  • Lewis RI, Carrion HM, Lockhart JI, Politano VA. Significance of asymptomatic bacteriuria in neurogenic bladder disease. Urology 13: 343–347, 1984
  • Schaeffer AJ, Sisney GA. Efficacy of norfloxacin in urinary tract infections: Biological effects on vaginal and faecal flora. J Urol 133: 628–630, 1985

References

  • Montgomerie JZ, Morrow JW. Pseudomonas colonization in patients with spinal cord injury. Am J Epidemiol 108: 328–336, 1978
  • Montgomerie JZ, Morrow JW. Longterm Pseudomonas colonization in spinal cord injury patients. Am J Epidemiol 112: 508–517, 1980
  • Grüneberg RN. Relationship of infecting urinary organism to the fecal flora in patients with symptomatic urinary tract infection. Lancet ii:766–767, 1969
  • Stamey TG, Mihara G. The effect of nalidixic acid on fecal flora and vaginal carriage of Enterobacteriaceae in 54 women. In: van der Waaij D, Verhoef J, eds. New criteria for antimicrobial therapy. Amsterdam: Excerpta Medica, 234–242, 1979
  • Weinstein L. The spontaneous occurrence of new bacterial infections during the course of treatment with streptomycin or penicillin. Am J Med Sci 214: 56–63, 1947
  • van der Waaij D. The colonization resistance of the digestive tract in man and animals. In: Fliedner ThM, ed. Clinical and experimental gnotobiotics. Zeitblatt für Bakteriologie, Suppl. 7. Stuttgart, New York: Gustav Fischer Verlag, 583–595, 1979
  • Cofsky RD, du Bouchet L, Landesman SJ. Recovery of norfloxacin in faeces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 26: 110–111, 1984
  • Chapman GH. The significance of sodium chloride in studies of Staphylococci. J Bact 50: 201–203, 1945
  • van Saene HKF, Stoutenbroek ChP, Zandstra DF, Miranda DR. A novel approach to infection control in the intensive care unit. Acta Anaesthesiol Belg 34: 193–208, 1983
  • Muytjens HL, van Veldhuizen GL, Welling GW, van der Ros-van de Repe J, Boerema JBJ, van der Waaij D. Selective decontamination of the digestive tract by pipemidic acid. Antimicrob Agents Chemother 24: 902–904, 1983
  • Welling GW. β-aspartyl glycine, an indicator of decreased colonization-resistance? In: van der Waaij D, Verhoef J, eds. New criteria for antimicrobial therapy. Amsterdam: Excerpta Medica, 65–71, 1979
  • Welling GW. Comparison of methods for the determination of β-aspartyl glycine in fecal super-natants of leukemic patients treated with antimicrobial agents. J Chromatogr 232: 55–62, 1982

References

  • Greenwood D, Osman M, Goodwin J, Cowlishaw WA, Slack R. Norfloxacin: Activity against urinary tract pathogens and factors influencing the emergence of resistance. J Antimicrob Chemother 13: 315–323, 1984
  • Vogel R, Deaney N, Round EM, VandenBerg MJ, Currie WJC. Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infection. J Antimicrob Chemother 13: Suppl B, 113–120, 1984
  • Crider SR, Colby SD, Miller LK, Harrison WO, Kerbs SJB, Berg SW. Treatment of penicillin-resistant Neisseria gonorrhea with oral norfloxacin. N Engl J Med 311: 137–140, 1984
  • Downs J, Andriole VT, Ryan JL. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomona aeruginosa. Antimicrob Agents Chemother 21: 670–672, 1982
  • Khan MY, Gruinger RP, Nelson SM, Klicker RE. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates. Antimicrob Agents Chemother 21: 848–851, 1982
  • Kumamoto Y, Ishigami J. Clinical experience with norfloxacin in urinary tract infections. Eur J Chemother Antibiotics 3: 31–39, 1983
  • Goldstein E, Cherubin C, Alpert M, Najem A, Ginsberg B, Eng R. Norfloxacin in the therapy of complicated and uncomplicated urinary tract infections: A comparative multicenter trial. Am J Med Suppl.; in press.
  • Lenette EH, ed. Manual of clinical microbiology. 3rd ed., Washington, D.C.; American Society for Microbiology, 1980
  • Shungu DL, Tutlane V, Gadesbusch HH. Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility with norfloxacin. J Clin Microbiol 18: 988–991, 1983
  • Giamarellou H, Tsagarakis J, Petrikkos G, Daikos GK. Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur J Clin Microbiol 2: 266–269, 1983
  • Guerra JG, Falcon E, Palomino JC, Benavente L, Antunez de Mayolo E. Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections. Eur J Clin Microbiol 2: 260–265, 1983
  • Watt B, Chait I, Kelset MC, Newsom SWB, Newsom RA, Smith J, Toase PD, Deaney NB, Round EM, Vogel R, Currie WJC. Norfloxacin versus cortrimoxazole in the treatment of uncomplicated urinary tract infections. J Antimicrob Chemother 13: Suppl. B: 89–94, 1984
  • Haase DA, Harding GKM, Thompson MJ, Kennedy JK, Urias BA, Ronald AR. Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora. Antimicrob Agents Chemother 26: 481–484, 1984

References

  • Khan MY, Siddiqui Y, Gruninger RP. Comparative in vitro activity of MK-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae. Antimicrob Agents Chemother 20: 265–266, 1981
  • Peeters M, Van Dyck E, Piot P. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae. Antimicrob Agents Chemother 26: 608–609, 1984
  • Sweet RL, Ohm-Smith MJ, Hadley WK. Comparative in vitro activity of norfloxacin and selected antimicrobial agents against urinary tract pathogens and Neisseria gonorrhoeae. J Antimicrob Chemother 10: 553–557, 1982
  • Wolfson JS, Hooper DC. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 28: 581–586, 1985
  • Swanson BN, Boppana VK, Vlasses PH, Rotmensch HH, Ferguson RK. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 23: 284–288, 1983
  • Crider SR, Colby SD, Miller LK, Harrison WO, Kerbs SBJ, Berg SW. Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin. NEJM 311: 137–140, 1984
  • Romanowski B, Wood H, Draker J, Tsianco MC. Norfloxacin in the therapy of uncomplicated gonorrhoea. Antimicrob Agents Chemother 30, 1986
  • Anand CM, Kadis EM. Evaluation of the Phadebact gonococcus test for confirmation of Neisseria gonorrhoeae. J Clin Microbiol 12: 15–17, 1980
  • Weisner PJ, Holmes KK, Sparling PF, Maness MJ, Bear DM, Gutman LT, Karney WW. Single doses of methacycline and doxycycline for gonorrhea: A cooperative study of the frequency and cause of treatment failure. J Infect Dis 127: 461–466, 1973
  • Russo ME, Thompson MI. Pharmacology of drugs used in venereology. In: Holmes KK, Mårdh PA, Sparling PF, Wiesner PJ, ed. Sexually transmitted diseases. New York: McGraw-Hill Book Company, 891–922, 1984
  • Washington AE. Experience with various antibiotics for treatment of anorectal gonorrhea. Sex Transm Dis 6 ( Suppl): 148–151, 1979
  • Washington AE. Update on treatment recommendations for gonococcal infections. Rev Infect Dis 4 ( Suppl): 758–771, 1982
  • Kraus SK. Incidence and therapy of gonococcal pharyngitis. Sex Transm Dis 6 ( Suppl): 143–147, 1979
  • Phillips I. B-lactamase-producing, penicillin-resistant gonococcus. Lancet 2: 656, 1976
  • Ashford WA, Golash RG, Hemming VG. Penicillinase-producing Neisseria gonorrhoeae. Lancet 2: 657–658, 1976
  • Siegel MS, Perine PL, Westbrook WG, de Jesus I. Epidemiology of penicillinase-producing Neisseria gonorrhoeae. In: Brooks GF, Gotschlich EC, Holmes KK, Sawyer WD, Young FE, eds. Immunobiology of Neisseria gonorrhoeae. American Society for Microbiology, Washington, D.C., 75–79, 1978
  • Thornsberry C, Jaffee H, Brown ST, Edwards T, Biddle JW, Thompson SE. Spectinomycin-resistant Neisseria gonorrhoeae. JAMA 237: 2405–2406, 1977
  • Centers for Disease Control. Penicillinase-resistant gonorrhoea—North Carolina. Morbidity Mortality Weekly Rep 32: 273–275, 1983
  • Richmond SJ, Paul ID, Taylor PK. Value and feasibility of screening women attending STD clinics for cervical chlamydial infections. Br J Vener Dis 56: 92–95, 1980
  • Lyeke E, Lowhagen GB, Hallhagen G, Johannison G, Ramstedt K. The risk of transmission of genital Chlamydia trachomatis infection is less than that of genital Neisseria gonorrhoeae infection. Sex Transm Dis 7: 6–10, 1980
  • Svensson L, Weström L, Mårdh PA. Chlamydia trachomatis in women attending a gynaecologist outpatient clinic with lower genital tract infection. Br J Vener Dis 57: 259–262, 1981
  • Swartz SL, Kraus SJ, Hermann KL, Stargel MD, Brown WJ, Allen SD. Diagnosis and etiology of non-gonococcal urethritis. J Infect Dis 138: 445–453, 1978
  • Terho P. Chlamydia trachomatis in gonococcal and post gonococcal urethritis. Br J Vener Dis 54: 326–329, 1978
  • Bradley SB, Fisher LM, Dalton HP. Recovery of Chlamydia trachomatis from patients of a southeastern venereal disease clinic. Am J Clin Pathol 73: 774–781, 1980
  • Bowie WR, Wang SP, Alexander ER, Floyd J, Forsyth PS, Pollock HM, Lin JL, Buchanan TM, Holmes KK. Etiology of non-gonococcal urethritis: Evidence for Chlamydia trachomatis and Urea-plasma urealyticum. J Clin Invest 59: 735–742, 1977
  • Handsfield HH, Alexander ER, Wang SP, Pedersen AHB, Holmes KK. Differences in the therapeutic response of chlamydia-positive and chlamydia-negative forms of non-gonococcal urethritis. J Am Vener Dis Assoc 2: 5–9, 1976
  • Meier-Ewert H, Weil G, Millott G. In vitro activity of norfloxacin against Chlamydia trachomatis. Eur J Clin Microbiol 2: 271–272, 1983
  • Heessen FWA, Muytjens HL. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin and nalidixic acid against Chlamydia trachomatis. Antimicrob Agents Chemother 25: 123–124, 1984

References

  • Gleckman R, Crowley M, Natsios GA. Therapy of recurrent invasive urinary tract infections in men. N Engl J Med 301: 887–880, 1979
  • Meares EM Jr, Stamey TA. Bacteriological localisation patterns in bacterial prostatitis and urethritis. Invest Urol 5: 492–518, 1968
  • Norrby SR, Jonsson M. Antibacterial activity of norfloxacin. Antimicrob Agents Chemother 23: 15–18, 1983
  • Neu HC, Labthavkul P. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of β-lactams, aminoglycosides and trimethoprim. Antimicrob Agents Chemother 22: 23–27, 1982
  • King A, Warren C, Shannon K, Philips I. In vitro antimicrobial activity of norfloxacin (MK-366). Antimicrob Agents Chemother 21: 604–607, 1982
  • Nicolle L, Harding GK. Susceptibility of clinical isolates of Staphylococcus saprophyticus to fifteen commonly used antimicrobial agents. Antimicrob Agents Chemother 22: 895–896, 1982
  • Downs J, Andriole VT, Ryan JL. In vitro activity of MK0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 21: 670–672, 1982
  • Bologna M, Vaggi L, Forchetti CM, Martini C. Bactericidal intraprostatic concentrations of norfloxacin. Lancet 2: 280, 1983
  • Bergerson MG, Thabet M, Roy R . Norfloxacin penetration into human renal and prostatic tissues. Antimicrob Agents Chemother 28: 349–350, 1985
  • Swanson BN, Boppana VK, Ulosses PH, Rotmensch HH, Ferguson RK. Norfloxacin dispository after sequentially increasing oral doses. Antimicrob Agents Chemother 23: 284–288, 1983
  • Bauer AW, Kirby WMM, Sherris JC, Turk M. Antibiotic susceptibility testing by a standard single disk method. Am J Clin Pathol 45: 493–496, 1966
  • Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. JASA 58: 690–700, 1963
  • Fisher RA (1935). The design of experiments. Oliver & Boyd, Edinburgh, London (1st ed. 1935, 7th ed. 1960) (7.4).
  • Mobley DF. Semen cultures in the diagnosis of bacterial prostatitis. J Urol 114: 83–85, 1975
  • Meares EM Jr. Long-term therapy of chronic bacterial prostatitis with trimethoprim-sulphamethox-azole. Canadian Med Assoc 112: 225–235, 1975
  • Smith JW, Jones SR, Reed WP . Recurrent urinary tract infections in men. Ann Intern Med 91: 544–548, 1979
  • Vogel R, Deaney NB, Round EM . Norfloxacin amoxycillin, cotrimoxazole and nalidixic acid— A summary of three-day and seven-day therapy studies in the treatment of urinary tract infections. J Antimicrob Chemother 13: 113–120 1984
  • Sabbaj J, Hoagland VL, Shih WJ. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother 27: 297–301, 1985

References

  • Stoll BJ, Glass RI, Huq IM, Khan MU, Holt JE, Banu H. Surveillance of patients attending a diarrhoeal disease hospital in Bangladesh. Br Med J 285: 1185–1188, 1982
  • Guerrant RI, Kirchhoff LV, Shields DS, Nations MK, Leslie J, de Suosa MA, Araujo JG, Correia LL, Sauer KT, McClelland KE, Trowbridge FL, Hughes JM. Prospective study of diarrhoeal illnesses in northeastern Brazil: Patterns of disease, nutritional impact, etiologies, and risk factors. J Infect Dis 148: 986–996, 1983
  • Ruiz-Palacios GM. Etiologic agents of acute diarrhoea: Bacterial and parasitic. In: Bellanti JA, ed. Acute diarrhoea: Its nutritional consequences in children. New York: Raven Press, 67–70, 1983
  • Mansuwan P, Lexomboon U, Sunakorn P, Harikul S, Roong-in S. Epidemiology of diarrhoeal disease in children in rural area of Thailand. J Pediat Soc Thailand 23: 31–53, 1984
  • Gurwith MJ, Williams TW. Gastroenteritis in children: A two-year review in Manitoba. I. Etiology. J Infect Dis 136: 239–247, 1977
  • Pickering LK, Evans DJ, Muñoz O, Evans DG, Olarte J, DuPont HL. Prospective studies of enteropathogens in children with diarrhoea in Houston and Mexico. J Pediatr 93: 383–388, 1978
  • Haltalin KC, Nelson JD, Hinton LV, Kusmiesz HT, Sladoje M. Comparison of orally absorbable and nonabsorbable antibiotics in shigellosis: A double-blind study with ampicillin and neomycin. J Pediatr 72: 708–720, 1968
  • Nelson JD, Kusmiesz HT, Jackson LH, Woodman E. Trimethoprim/sulfamethoxazole therapy for shigellosis. JAMA 235: 1239–1243, 1976
  • Wheeler WE. Spread and control of Escherichia coli diarrhoeal disease. Ann NY Acad Sci 66: 112–117, 1956
  • Kessner DM, Shaughnessy HJ, Googins J. An extensive community outbreak of diarrhoea due to enteropathogenic Eschierchia coli O111: B4:I. Epidemiologic studies. Am J Hyg 76: 27–43, 1962
  • Rowe B, Threlfall EJ. Drug resistence in gram-negative aerobic bacilli. Brit Med Bull 40: 68–76, 1984
  • Olarte J, Galindo E. Salmonella typhi resistant to chloramphenicol, ampicillin and other antimicrobial agents: Strains isolated during an extensive typhoid fever epidemic in Mexico. Antimicrob Agents Chemother 4: 597–601, 1973
  • Tiemens KM, Shipley PL, Correia RA, Shields DS, Guerrant RL. Sulfamethoxazole-trimethoprim-resistant Shigella flexneri in Northeastern Brazil. Antimicrob Agents Chemother 25: 653–654, 1984
  • Vanhoof R, Gordts B, Dierickx R, Coignau H, Butzler JP. Bacteriostatic and bactericidal activities of 24 antimicrobial agents against Campylobacter fetus subsp. jejuni. Antimicrob Agents Chemother 18: 117–121, 1980
  • Holmes B, Brogden RN, Richards DM. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 30: 482–513, 1985
  • Cofsky RD, DuBouchet L, Landesman SH. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 26: 110–111, 1984
  • Cristiano P, Jovene MR, Lobello R, Corcione F, Giordano B. Biliary pharmacokinetics of norfloxacin. In: Daikos GK, Giamarellou H, eds. Proceedings, IV Mediterranean Congress of Chemotherapy. Chemioterapia 4 (Suppl. 2): 494–495, 1985
  • Shungu DL, Weinberg E, Gadebusch HH. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob Agents Chemother 23: 86–90, 1983
  • Goossens H, De Mol P, Coignau H, Levy J, Grados O, Ghysels G, Innocent H, Butzler JP. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against eneropathogens. Antimicrob Agents Chemother 27: 388–392, 1985
  • Ruiz-Palacios GM, Huazano F, Giraud MC, Jacobo J, Schuller D. Overview of in vitro and clinical experience with norfloxacin in gastrointestinal infections. In: Daikos GK, Giamarellou H, eds. Proceedings, IV Mediterranean Congress of Chemotherapy. Chemioterapia 4 (Suppl. 2): 353–355, 1985
  • Caldwell MB, Walker RI, Stewart SD, Rogers JE. Simple adult rabbit model for Campylobacter jejuni enteritis. Infect Immun 42: 1176–1182, 1983
  • Ruiz-Palacios GM, López-Vidal Y, López-Vidal AB, Torres J, Rubio S. Systemic and local immune response in experimental Campylobacter infection. In: Skirrow MB, Butzler JP, eds. Campylobacter II. Southampton, England: PHLS, 115–116, 1983
  • Johnson PC, Ericsson CD, Morgan DR, DuPont HL. Prophylactic norfloxacin for acute travellers diarrhoea (Abstract). Southern Soc Clin Invet, January 1985, New Orleans.

References

  • Burke PJ, Braine HG, Rathbun HK, Owens AH Jr. The clinical significance and management of fever in acute myelocytic leukemia. The Johns Hopkins Med J 139: 1–12, 1976
  • Pizzo PA, Commers J, Cotton D, Gress J, Hathorn J, Hiemenz J, Longo D, Marshall D, Robichaud KJ. Approaching the controversies in antibacterial management of cancer patients. Am J Med 76: 436–48, 1984
  • Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72: 101–11, 1982
  • Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284: 1061–5, 1971
  • Burke PJ, Karp JE, Barine HG, Vaughan WP. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res 37: 2138–46, 1977
  • Dosik GM, Luna M, Valdivieso M, McCredie KB, Gehan EA, Gil-Extremera B, Smith T, Bodey G. Necrotizing colitis in patients with cancer. Am J Med 67: 646–56, 1979
  • Prolla JC, Kirsner JB. The gastrointestinal lesions and complications of the leukemias. Ann Internal Med 61: 1084–100, 1964
  • Slavin RE, Dias MA, Saral R. Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols: A clinical-pathologic study of 33 patients. Cancer 42: 1747–59, 1979
  • Greene WH, Moody M, Schimpff S, Young VM, Wiernik PH. Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in cancer center. Ann Int Med 79: 684–9, 1973
  • Schimpff SC. Infection prevention during profound granulocytopenia. Ann Int Med 93: 358–61, 1980
  • Sleijfer DTh, Mulder NH, de Vries-Hospers HGF, Fidler V, Nieweg HO, van der Waaij D, van Saenes HKF. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Europ J Cancer 16: 859–69, 1980
  • Gualtieri RJ, Donowitz GR, Kaiser DL, Hess CE, Sande MA. Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 74: 934–40, 1983
  • Gurwith MJ, Brunton JL, Lank BA, Harding GKM, ronald AR. A prospective controlled investigation of prophylactic trimethoprimnn/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 66: 348–56, 1979
  • Weiser B, Lange M, Fialk MA, Singer C, Szatrowski TH, Armstrong D. Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: A controlled trial. Ann Int Med 95: 436–8, 1981
  • Dekker AW, Rozenberg-Arska M, Sixma JJ, Verhoef J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukemia. Ann Int Med 95: 555–9, 1981
  • Wade JC, Schimpff SC, Hargedon MT, Fortner CL, Young VM, Wiernik PH. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med 304: 1057–62, 1981
  • Bodey GP, Keating MJ, McCredie KB, Elting L Rosenbaum B, Freireich EJ. Prospective randomized trial of antibiotic prophylaxis in acute leukemia. Am J Med 78: 407–16, 1985
  • King K. Prophylactic non-absorbable antibiotics in leukaemic patients. J Hyg Camb 85: 141–51, 1980
  • Levine AS, Siegel SE, Schreiber AD, Hauser J, Preisler H, Goldstein IM, Seidler F, Simon R, Perry S, Bennett JE, Henderson ES. Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 288: 477–83, 1973
  • Schimpff SC, Greene WH, Young VM, Fortner CL, Jepsen L, Cusack N, Block JB, Wiernik PH. Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Int Med 82: 351–8, 1975
  • Storring RA, Jameson B, McElwain TJ, Wiltshaw E, Spiers ASD, Gaya H. Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukemia. Lancet 2: 837–40, 1977
  • Henry SA. Chemoprophylaxis of bacterial infections in granulocytopenic patients. Am J Med 76: 645–51, 1984
  • Murray BE, Rensimer ER, Du Pont HL. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim-sulfamethoxazole. N Engl J Med 306: 130–5, 1982
  • Wilson JM, Gurney DG. Failure of oral trimethoprim-sulfamethoxazole prophylaxis in acute leukemia. Isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia. N Engl J Med 306: 16–20, 1982
  • Norrby SR, Jonsson M. Antibacterial activity of Norfloxacin. Antimicrob Agents Chemother 23: 15–18, 1983
  • Shungu DL, Weinberg E, Gadebusch HH. In vitro antibacterial activity of Norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob AGents Chemother 23: 86–90, 1983
  • Wolfson JS, Hooper DD. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 28: 581–6, 1985
  • Crumplin GC, Kenwright M, Hirst T. Investigations into the mechanism of action of the antibacterial agent Norfloxacin. J Antimicrob Chemother 13 ( Suppl B:) 9–23, 1984
  • Hooper DC, Wolfson JS. The fluoroquinolones: Pharmacoalogy, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 28: 716–21, 1985
  • Weisser J, Wiedemanan B. Elimination of plasmids by new 4-quinolones. Antimicrob Agents Chemother 28: 700–2, 1985
  • Vaughan WP, Karp JE, Burke PJ. Two cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 64: 975–80, 1984
  • Kaizer H, Stuart RK, Brookmeyer R, Beschorner WE, Braine HG, Burns WH, Fuller DJ, Korbling M, Mangan KF, Saral R, Sensenbrenner L, Shadduck RK, Shende AC, Tutschka PJ, Yeager AM, Zinkham WH, Colvin OM, Santos, GW. Autologous bone marrow transplantation (BMT) in acute leukemia: A phase I studied of in vitro treatment of marrow with 4-hydroperoxy-cyclophosphamide (4HC) to purge tumor cells. Blood 65: 1504–10, 1985
  • Karp JE, Dick J, Angelopulos C, Bamberger BJ, Redden T, Saral R, Burke PJ. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia: A randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med, in press, 1986
  • Holdeman LV, Cato EP, Moore WEC, ed. Anaerobic Laboratory Manual, 4th ed. VPI Anaerobe Laboratory, Blacksburg, Virginia, 1977
  • Swanson BN, Boppana VK, Vlasses PH, Rotmensch HH, Ferguson RK. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 23: 284–8, 1983

References

  • Ito A, Inoue M, Koga H . In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother 17: 103–108, 1980
  • Gadebusch HH, Shungu DL, Weinberg E, Chung SK. Comparison of the antibacterial activity of norfloxacin (MK-0366, AM-715), a new organic acid, with that of other orally absorbed chemotherapeutic agents. Infection 10: 41–44, 1982
  • Khan MY, Gruminger RP, Nelso SM, Klicker RE. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against uriniary bacterial isolates. Antimicrob Agents Chemother 21: 842–851, 1982
  • King A, Warren C, Shannon K, Philips I. In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother 21: 604–607, 1982
  • Norrby SR, Jonsson M. Antibacterial activity of norfloxacin. Antimicrob Agents Chemother 23: 284–288, 1983
  • Neu HC, Labthavkul P. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of β-lactams, aminoglycosides and trimethoprim. Antimicrob Agents Chemother 22: 23–27, 1982
  • Shungu DL, Weinberg E, Gadebusch HH. In vitro antibacterial activities of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob Agents Chemother 23: 86–90, 1983
  • Carlson JR, Thornton SA, DuPont HL, West AH, Mathewson JJ. Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens. Antimicrob Agents Chemother 24: 509–513, 1983
  • Swanson BN, Boppana VK, Ulosses PH, Rotmensch HH, Ferguson RK. Norfloxacin dispository after sequentially increasing oral doses. Antimicrob Agents Chemother 23: 284–288, 1983
  • Cofsky RD, DuBouchet L, Landesman SH. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 26: 110–111, 1984
  • Sabbaj J, Hoagland VL, Shih WJ. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother 27: 297–301, 1985
  • Johnson PC, Ericsson CD, Morgan DR, DuPont HL. Prophylactic norfloxacin for acute travellers' diarrhoea. Clinical Research 32: 870A, 1984
  • Sabbaj J, Hoagland VL, Cook T. Norfloxacin versus cotrimoxazole in the treatment of recurrent urinary tract infections in men. Scand J Infect Dis, Suppl. 48: 48–53, 1986
  • Cohn DL, Reller LB, Paisley JW, Ciesielski CA, Wood J, Penley KA, Coe CA, Mason SR. Controlled clinical trial of norfloxacin for fecal leukocyte. Positive diarrhoea: Background and preliminary results. Thirteenth International Congress of Chemotherapy. SS4.6/9, Part 38, 41–45, 1983
  • Gotuzzo E, Guerra JG, Benavente L, Lopera J, Delgado F, Palomino JC. Treatment (Rx) of chronic carrier state of Salmonella typhi (CCSST) with norfloxacin (NF). ICAAC. Abstract 64, 1985
  • Gurwtih MJ, Rabin HR, Love K. The cooperative antibiotic diarrhoea study group. Diarrhoea associated with clindamycin and ampicillin therapy: Preliminary results of a cooperative study. J Infect Dis 135 ( S): S104–110, 1977

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.